Impact of Adjuvant Chemotherapy in Elderly Breast Patients in Taiwan, A Hospital-Based Study

  • Lee, Hsiu Chuan (Department of Internal Medicine, Chi-Mei Medical Center) ;
  • Chen, Wei Yu (Department of Internal Medicine, Chi-Mei Medical Center) ;
  • Huang, Wen Tsung (Department of Surgery, Chi-Mei Medical Center) ;
  • Cheng, Kuo Chen (Department of Internal Medicine, Chi-Mei Medical Center) ;
  • Tian, Yu Feng (Department of Surgery, Chi-Mei Medical Center) ;
  • Ho, Chung Han (Department of Medical Research, Chi-Mei Medical Center) ;
  • Tsao, Chao Jung (Department of Hematology-Oncology, Chi-Mei Medical Center) ;
  • Feng, Yin Hsun (Department of Internal Medicine, Chi-Mei Medical Center)
  • Published : 2016.10.01


Purpose: Decisions as to whether to provide adjuvant treatment in older breast cancer patients remains challenging. Side effects of chemotherapy have to be weighed against life expectancy, comorbidities, functional status, and frailty. To aid decision-making, we retrospectively analyzed 110 women with breast cancer treated with a curative intention from 2006 to 2012. Survival data with clinical and pathological parameters were evaluated to address the role of adjuvant chemotherapy in this study population. Method: A total of 110 elderly (>70 years) patients that received mastectomy at two hospitals in Taiwan were observed retrospectively for a medium of 51 months. After mastectomy, patients received conservative treatment or adjuvant chemotherapy, or hormone therapy following clinical guidelines or physician's preference. Data were collected from the cancer registry system. Results: Median age at diagnosis was 75.7 years. Thirty-five percent of patients received adjuvant chemotherapy, these having a significantly younger age ($mean=74.0{\pm}5.3$ vs $77.5{\pm}5.3$, p<0.001) and higher tumor staging (p=0.003) compared with their non-chemotherapy counterparts.Five-year overall survival was non-significantly higher in patients who received adjuvant chemotherapy (with chemotherapy 64.2% vs without chemotherapy 62.6%, p=0.635), while five-year recurrence free survival was non-significantly lower (with chemotherapy 64.1% vs without chemotherapy 90.5%, p=0.80). Conclusions: In this analysis, adjuvant chemotherapy tended to be given to patients with a younger age and higher tumor staging at our institute. It was not associated with any statistically significant improvement in survival and recurrence rate. Until age specific recommendations are available, physicians must use their clinical judgment and assess the tumor biology with the patient's comorbidities to make the best choice. Clinical trials focusing on this critical issue are warranted.


Breast cancer;adjuvant chemotherapy;elderly


  1. Angarita FA, Chesney T, Elser C, et al (2015). Treatment patterns of elderly breast cancer patients at two Canadian cancer centres. Eur J Surg Oncol, 41, 625-34.
  2. Bastiaannet E, Portielje JE, van de Velde, et al (2011). Lack of survival gain for elderly women with breast cancer. Oncologist, 16, 415-23.
  3. Bergen ES, Tichy C, Berghoff, et al (2016). Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Res Treat, 157, 91-9.
  4. Biganzoli L, Wildiers H, Oakman C, et al (2012). Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol, 13, 148-60.
  5. Crivellari D, Bonetti M, Castiglione-Gertsch, et al (2000). Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol, 18, 1412-22.
  6. Collaborative G, Peto R, Davies C, et al (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379, 432-44.
  7. Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol, 24, 2757-64.
  8. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol, 24, 2750-56.
  9. Jueckstock J, Kasch F, Jaeger B, et al (2015). Adjuvant therapeutic decisions in elderly breast cancer patients: the role of chemotherapy in a retrospective analysis. Arch Gynecol Obstet, 292, 1101-07.
  10. Karavasilis V, Papadimitriou C, Gogas H, et al (2016). Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Clin Breast Cancer, 16, 291-98.
  11. Klepin HD, Pitcher BN, Ballman KV, et al (2014). Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). J Oncol Pract, 10, 285-92.
  12. Le Saux O, Ripamonti B, Bruyas A, et al (2015). Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging, 10, 157-74.
  13. Leonard R, Ballinger R, Cameron D, et al (2011). Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br J Cancer, 105, 1260-66.
  14. Muss HB, Berry DA, Cirrincione CT, et al (2009). Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med, 360, 2055-65.
  15. Pierga JY, Girre V, Laurence V, et al (2004). Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast, 13, 369-75.
  16. Rosenstock AS, Lei X, Tripathy D, et al (2016). Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat, 157, 339-50.
  17. Shen YC, Chang CJ, Hsu C, et al (2005). Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev, 14, 1986-90.
  18. Soubeyran P, Bellera C, Goyard J, et al (2014). Screening for vulnerability in older cancer patients: the Oncodage prospective multicenter cohort study. PLoS One, 9, e115060.
  19. Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108.
  20. Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. Jama, 285, 2750-56.
  21. Westphal T, Rinnerthaler G, Mlineritsch B (2016) Adjuvant medical treatment for breast cancer in elderly and old women. Memo, 9, 17-19.
  22. Wildiers H, Kunkler I, Biganzoli L, et al (2007). Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol, 8, 1101-15.